MMCAP Infuse Notice of RFP 34056 - Distribution of Vaccines and Vaccine-related Products

MMCAP Infuse, a governmental group purchasing organization, has issued Request for Proposal (RFP) 34056 seeking qualified distributors for comprehensive vaccine and vaccine-related product distribution services across multiple jurisdictions, with a specific focus on the state of Oregon. The RFP aims to establish contracts with distributors capable of providing national or regional distribution coverage for routine, seasonal, and specialized vaccines, including flu, COVID-19, toxoids, diagnostic agents, and monoclonal antibodies used in immunization settings. Potential distributors must meet stringent minimum qualifications, including maintaining an authorized wholesaler/distributor relationship with at least 10 listed vaccine suppliers, demonstrating chargeback capabilities with 8 suppliers, and being licensed to distribute pharmaceuticals/vaccines in a minimum of 5 states. Evaluation criteria will encompass vendor experience, inventory management capabilities, customer service quality, reporting and data transfer proficiency, and overall cost competitiveness. The proposal submission deadline is May 21, 2024, at 2:00 pm Central Time, with an anticipated contract effective date no later than September 1, 2024, and an initial contract term of two years potentially extendable through three additional one-year periods.

The RFP includes preference points for Minnesota-certified targeted group/economically disadvantaged businesses and veteran-owned businesses, indicating a commitment to diverse vendor participation. While specific set-aside percentages are not detailed, the solicitation suggests opportunities for businesses meeting these designations. The contract will include a 3% administrative fee on all sales to MMCAP Infuse members, and vendors will be required to charge members the contracted rates established by MMCAP Infuse and its suppliers. Currently, MMCAP Infuse has three contracted vendors for these services, suggesting potential for multiple award scenarios. Vendors must demonstrate robust capabilities including regulatory compliance, sufficient vaccine stock maintenance, reliable customer service, customizable invoicing, flexible delivery options, and comprehensive cybersecurity measures. While specific contract values are not explicitly stated, the extensive product listing in the accompanying spreadsheet and the nationwide distribution scope indicate a potentially significant procurement opportunity with substantial financial implications for selected distributors.